In patients with axial spondyloarthritis (axSpA) and persistent disease activity for which adapting treatment is recommended, treatment intensification should be considered for patients with persistently high disease activity. EULAR—The European Alliance of Associations for Rheumatology—in collaboration with the Assessment of SpondyloArthritis international Society (ASAS), states that high disease activity should be based on a composite score, the Ankylosing Spondylitis Disease Activity Score (ASDAS) with a cutoff ≥2.1.
This article was originally published on MedicalXpress.com
